Aurinia Pharmaceuticals
AUPH
About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Employees: 300
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
74% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $7.42M
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
2% more funds holding
Funds holding: 210 [Q1] → 214 (+4) [Q2]
10% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 62
1% less capital invested
Capital invested by funds: $499M [Q1] → $493M (-$5.13M) [Q2]
2.04% less ownership
Funds ownership: 45.14% [Q1] → 43.1% (-2.04%) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
RBC Capital
Douglas Miehm
|
$9
|
Outperform
Maintained
|
1 Aug 2025 |
|
HC Wainwright & Co.
Arthur He
|
$17
|
Buy
Assumed
|
30 Jul 2025 |
Financial journalist opinion
